

# Like Parent, Like Metabolite:

Do antibiotics and their transformation products exert comparable selective pressures?


**Pooja Lakhey**

Queensland Alliance for Environmental Health Sciences, The University of Queensland  
Environment and Sustainability Institute, University of Exeter

22/10/2025

A partnership between


# The environment plays a major role in resistance evolution



# What are antibiotic TPs?

Modified breakdown products of antibiotics — but not necessarily harmless.

Process	Examples
Biological	Microbial metabolism
Chemical	Hydrolysis, oxidation
Physical	Photodegradation




**Why it matters:** Transformation products can **persist**, may remain **biologically active**, and potentially **contribute to AMR selection** — yet they're often ignored in risk assessments.

# Introduction

# Aims

# Methodology

# Progress




Concentration of antimicrobials and the TPs in wastewater influent in Australia. (Li et al. 2024)

# Introduction

# Aims

# Methodology

# Progress





Concentration of antimicrobials and the TPs in wastewater influent in Australia. (Li et al. 2024)

# Introduction

## Aims


## Methodology

## Progress



Concentration of antimicrobials and the TPs in wastewater effluent in Australia. (Li et al. 2024)

# From detection to impact: Do TPs drive antibiotic resistance?



Bacterial survival under different antibiotic concentrations over time.

# Introduction



# Aims

# Methodology

# Progress




Sample collection



SELECT Assay





Data analysis



Target genes:


- *intl1*
- 16S rRNA



Evolution experiment




## Growth inhibition profiles for Ciprofloxacin and Desethylene ciprofloxacin (SELECT Assay)




Area under the curve (AUC) of bacterial growth (OD600) in response to increasing concentrations of CIP and deCIP.

## Growth inhibition profiles for Moxifloxacin and Moxifloxacin-N-sulfate (SELECT Assay)






# Fluoroquinolones




Effect of fluoroquinolone antibiotics and their transformation products on *int1* prevalence over 7 days.



# Fluoroquinolones




Comparison of mean *int11* prevalence between antibiotics and their TPs. Bar plots show the average *int11* abundance across replicates for each compound pair after 7-day exposure.



Log<sub>10</sub> fold change in *int11* prevalence (Day 7 relative to Day 0) across compound treatments.

# Conclusion

- All TPs tested showed some ability to increase *intI1* prevalence, indicating potential for AMR selection.
- In most cases, TPs had lower selective pressure than parent antibiotics. However, some metabolites (e.g. dmOFL) showed comparable or even higher enrichment than parents, highlighting compound-specific risks.
- Transformation products should not be ignored in AMR risk assessments.



## Acknowledgement



Dr Jake O'Brien  
Sr. Research Fellow



Prof Kevin Thomas  
QAEHS Director



Dr April Hayes  
Research Fellow



Prof William Gaze  
Prof. of microbiology



Dr Aimee Murray  
Senior Lecturer



Dr Anne Leonard  
Senior Lecturer

UQ-Exeter Institute  
AMR Group at QAEHS and ESI

